This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
Young women who become pregnant while in remission from Hodgkin lymphoma are not at increased risk of cancer recurrence, according to a study published in the Journal of Clinical Oncology.
A prospective study of more than 100,000 Americans suggests that consuming citrus fruit, specifically whole grapefruit and orange juice, frequently may increase one’s chance of developing melanoma. However, experts stress more research is needed and caution against making any dietary changes based on this study at this time.
According to an analysis published in the Journal of Clinical Oncology, patients and survivors who smoked prior to their cancer diagnosis had an up to five times higher risk of developing a second primary cancer than patients who never smoked.
One in three patients with cancer experiences anxiety or other mental health challenges, according to a study published in the Journal of Clinical Oncology. This is the largest and most comprehensive study to date assessing the mental and emotional health of patients with cancer using a standardized, diagnostic face-to-face interview.
New findings from a large group of patients from the national Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial show that men who have a specific form of baldness – at both the front and crown of the head – at the age of 45 have a 40% increased risk of developing aggressive prostate cancer (usually indicates a faster growing tumor resulting in poorer prognosis, relative to “non-aggressive” prostate cancer) later in life, compared to men with no baldness at that age. However, the researchers did not find a link between any type of baldness and risk of non-aggressive prostate cancer.
A large, long-term study showed for the first time that women with BRCA1 mutations should undergo preventive surgical removal of the ovaries (prophylactic oophorectomy) by age 35 to achieve the greatest reduction in ovarian cancer risk. Researchers showed that waiting until a later age to have the surgery was associated with a significantly higher ovarian cancer risk. In addition, the investigators reported for the first time that prophylactic oophorectomy reduces the overall risk of death by 77 percent among women with either a BRCA1 or BRCA2 mutation.
A large, long-term follow-up study showed that people who were overweight or obese years before their pancreatic cancer diagnosis tend to have more advanced stage at diagnosis and shorter survival. Prior research had suggested that having a higher body mass index (BMI) increases one’s risk of developing pancreatic cancer. This is the first prospective study to demonstrate that BMI also affects outcomes after diagnosis.
An analysis of data collected in a large retrospective study showed that married patients tend to live longer after a cancer diagnosis than unmarried patients. Married patients are also more likely to have earlier-stage cancer at diagnosis and more likely to receive appropriate treatments, such as surgery and radiation therapy. The findings also suggest that more effort should be invested in improving social support services for unmarried patients with cancer.
New findings from a retrospective study suggest that targeted anti-HER2 therapy may slow disease progression in patients with advanced lung cancer who carry a specific alteration in HER2—a protein that controls cancer growth and spread, found on some cancer cells, such as breast, ovarian, and lung cancer cells.
New findings from a clinical trial in patients with colorectal cancer and inoperable metastases in the liver (cancer that has spread from the colon or rectum to the liver) suggest that combination treatment with standard therapy and targeted drug cetuximab (Erbitux) caused significant shrinkage of metastases, making successful surgery feasible.